Table Of Content

Breast Cancer Research and Treatment 32: 335, 1994. © 1994 Kluwer Academic Publishers. Printed in the Netherlands. Author index, Volume 32 Alama A 311 Double JA 269 Maemura M 239 ReinerG 165 Allred DC 5,13,,39 Maenpaa JU 57 Repetto L 311 Arndt D 269 EckardtJ 67 Manie S 213 Retsky MW 319 Asongwe G 269 Elbe B_ 187 Manotti L 221 Roseto A 139 Aubert JP 139 Elledge RM 39 Mason BH 203 Rossi B 213 Axelsson CK 281 McCarty KS Jr 327 Rosso R 311 Fenichel P 213 Meazza R 311 Rudas M_ 165 Baker WJ 57 Fichtner I 187,269 Meneghetti C 97 Baldini E 311 Floyd LJ 119 Merlini L 311 Sasaki A 73 BalslevI 281 Fuqua SAW Mistro D 139 Saul G-J_ 187 Bame PD 319 5,13,49,67,177 Mittlbéck M_ 165 Savoldi L 221 Barbieri F 311 Mouridsen H 281 Schouten LJ 197 Ben-EzraJ 261 GardinG 311 Mundy GR 73 Schutte B 197 Benedix M_ 177 Giannessi PG 311 Murphy LC 153 Seymour L 229 Berois N 139 Gnant MFX_ 165 Murphy LJ 153 Siegle RL 119 Bezwoda WR 229 Grass L 291 Skinner SJM 203 Bibby MC 269 Guazzi A 221 Naldi N 221 Staiger M 327 Blijham GH 197 Naso C 311 Sutherland DJA 301 Borochovitz D 327 Haensch W_ 187 Naundorf H_ 187,269 Swartzendruber DE Bozzetti C 221 Harris KB 327 Neumayer R 165 319 Nizzoli R 221 Hilsenbeck SG 67,105 Calvo F 139 Thyss A 213 Hofman P 213 Camisa R 221 O’Connell P 5,13 Holdaway IM 203 Camoriano A 311 Howes L 97 Odom-Maryon T 261 van Assche C_ 197 Campora E 311 Oesterreich S 67,177 Hsi B-L 213 Von Hoff DD 67 Carstensen B 281 Ollom CM_ 119 Hupperets PS 197 Chamness GC _ 1,177 Orang-Khadivi K 119 Wagman LD 261 Chen G 19 Osborne CK Clark GM_ 105 JagerJ 197 1,5,13,39,49,67,97,105 Wardwell RH 319 Cocconi G 221 Jakesz R 165 Osinaga E 139 Weng C-N 177 Julian TB 327 Wiebe VJ 57 Conte PF 311 Coutts A 153 Jungmann S 269 Pancino G 139 Williams RF 119 Wurz GT 57 Cox LA 19 Pekkel V 5 Kay RG 203 Pezner RD 261 Davis PL 327 KlementavicieneJ 327 Pierce BL 119 Yee D 85 de Jong J 197 Koehler RE 57 Porchet N 139 Yoneda T 73 De Cremoux P 139 Koester SK 57 Pronzatto P 311 YuH 291,301 De Laurentiis M Krieg S 177 105,113 Kummer A_ 165 Rasmussen BB 281 Zarghami N 291 DeGregorio MW 57 Ravdin PM _ 105,113 Zedeler K 281 Diamandis EP 291,301 Lee EY-HP 19 Reinecke S_ 187 Zeisig R 269 Dickson RB 239 LeMaistre CF 97 Reiner A_ 165 Zschiesche W_ 187 Breast Cancer Research and Treatment 32: 335, 1994. © 1994 Kluwer Academic Publishers. Printed in the Netherlands. Author index, Volume 32 Alama A 311 Double JA 269 Maemura M 239 ReinerG 165 Allred DC 5,13,,39 Maenpaa JU 57 Repetto L 311 Arndt D 269 EckardtJ 67 Manie S 213 Retsky MW 319 Asongwe G 269 Elbe B_ 187 Manotti L 221 Roseto A 139 Aubert JP 139 Elledge RM 39 Mason BH 203 Rossi B 213 Axelsson CK 281 McCarty KS Jr 327 Rosso R 311 Fenichel P 213 Meazza R 311 Rudas M_ 165 Baker WJ 57 Fichtner I 187,269 Meneghetti C 97 Baldini E 311 Floyd LJ 119 Merlini L 311 Sasaki A 73 BalslevI 281 Fuqua SAW Mistro D 139 Saul G-J_ 187 Bame PD 319 5,13,49,67,177 Mittlbéck M_ 165 Savoldi L 221 Barbieri F 311 Mouridsen H 281 Schouten LJ 197 Ben-EzraJ 261 GardinG 311 Mundy GR 73 Schutte B 197 Benedix M_ 177 Giannessi PG 311 Murphy LC 153 Seymour L 229 Berois N 139 Gnant MFX_ 165 Murphy LJ 153 Siegle RL 119 Bezwoda WR 229 Grass L 291 Skinner SJM 203 Bibby MC 269 Guazzi A 221 Naldi N 221 Staiger M 327 Blijham GH 197 Naso C 311 Sutherland DJA 301 Borochovitz D 327 Haensch W_ 187 Naundorf H_ 187,269 Swartzendruber DE Bozzetti C 221 Harris KB 327 Neumayer R 165 319 Nizzoli R 221 Hilsenbeck SG 67,105 Calvo F 139 Thyss A 213 Hofman P 213 Camisa R 221 O’Connell P 5,13 Holdaway IM 203 Camoriano A 311 Howes L 97 Odom-Maryon T 261 van Assche C_ 197 Campora E 311 Oesterreich S 67,177 Hsi B-L 213 Von Hoff DD 67 Carstensen B 281 Ollom CM_ 119 Hupperets PS 197 Chamness GC _ 1,177 Orang-Khadivi K 119 Wagman LD 261 Chen G 19 Osborne CK Clark GM_ 105 JagerJ 197 1,5,13,39,49,67,97,105 Wardwell RH 319 Cocconi G 221 Jakesz R 165 Osinaga E 139 Weng C-N 177 Julian TB 327 Wiebe VJ 57 Conte PF 311 Coutts A 153 Jungmann S 269 Pancino G 139 Williams RF 119 Wurz GT 57 Cox LA 19 Pekkel V 5 Kay RG 203 Pezner RD 261 Davis PL 327 KlementavicieneJ 327 Pierce BL 119 Yee D 85 de Jong J 197 Koehler RE 57 Porchet N 139 Yoneda T 73 De Cremoux P 139 Koester SK 57 Pronzatto P 311 YuH 291,301 De Laurentiis M Krieg S 177 105,113 Kummer A_ 165 Rasmussen BB 281 Zarghami N 291 DeGregorio MW 57 Ravdin PM _ 105,113 Zedeler K 281 Diamandis EP 291,301 Lee EY-HP 19 Reinecke S_ 187 Zeisig R 269 Dickson RB 239 LeMaistre CF 97 Reiner A_ 165 Zschiesche W_ 187 Breast Cancer Research and Treatment 32: 337-341, 1994. © 1994 Kluwer Academic Publishers. Printed in the Netherlands. Subject index, Volume 32 adhesion molecules bone metastasis in osteolytic bone metastasis 73-84 cytokines, osteoclasts, and cell adhesion involvement in metastasis — review 239-260 molecules 73-84 adjuvant chemotherapy enhanced by parathyroid hormone related protein abstracts S37-S38 (PTHrP) S91 alkylphosphocholines nude mouse model 73-84 antitumor activity in ER-negative tumors 269- breast cancer cell lines 279 two new human lines in nude mice — androgens preclinical drug testing 187-196 low urine and plasma levels and poor prognosis breast conservation 203-212 abstracts S41-S42 angiogenesis with clear margins — radiation therapy without abstracts S60 local boost 261-267 animal models of bone metastasis 73-84 cadherins of tamoxifen resistance 49-55 in osteolytic bone metastasis 73-84 two new human breast cancer lines in nude mice involvement in metastasis — review 239-260 — preclinical drug testing 187-196 cell adhesion molecules antiestrogens see adhesion molecules pure steroidal, in overcoming tamoxifen cell biology resistance 49-55 abstracts S$78-S83 regulation of IGF binding proteins 153-164 chemotherapy antigens abstracts S62-S66,S93 Tn-related tumor-associated acidic glycoprotein alkylphosphocholines — activity in ER-negative 139-152 tumors 269-279 atypical ductal hyperplasia for advanced disease — abstracts $33-S37 see premalignant breast disease primary — enhanced effectiveness in high TLI autocrine growth factors group 311-318 the IGF system as a target for therapy 85-95 clonal progression axillary dissection premalignant and associated invasive breast abstracts S39-S41 disease 5-12 cost-effectiveness S92 complement regulatory proteins axillary lymph nodes high CD46 (and absent CD55) in malignant improved microstaging S94 breast cells 213-219 computer modeling benign breast disease Gompertzian vs. stochastic growth — see also premalignant breast disease predictions for treatment 319-325 bisphosphonates correspondence analysis against bone metastases 73-84 in integration of prognostic factor data 105-112 bone marrow support cost-effectiveness with high-dose chemotherapy — abstracts S63- abstracts $73-S74 S66 of axillary dissection S92 338 Subject index, Vol. 32 Cox proportional hazards model evolution of breast cancer (cont.) in integration of prognostic factor data 105-112 immunohistochemical markers of progression cytokines stages 13-18 abstracts $54-S57 increased complement regulatory pruein CD46 with increased malignancy 213-219 detection by surface electropotential evaluation S92 fine needle aspiration detection and diagnosis for multiple immunocytochemical assays of abstracts S86-S87 breast tumors 221-228 diet flow cytometry abstracts S90 abstracts S53-S54 doxorubicin in monitoring drug effects 57-65 enhanced dose response with erbB-2 ploidy and S-phase in primary tumors vs. their overexpression S32 nodal metastases 197-202 resistance induced by hsp®7 67-71 drug ivsistance genetics abstracts S$38-S39 abstracts S75-S77 and heat shock proteins 67-71 frequent deletion of the CDK4 inhibitor gene partial reversal by protein kinase C INK4 S92 pseudosubstrates S31 linkage analysis of candidate loci S29 resensitization by toremifene 57-65 glycoproteins ductal carcinoma in situ (DCIS) Tn-related tumor-associated antigen 139-152 abstracts S43-S44 growth factors clonal relationship of breast cancer progression abstracts S54-S57 stages 5-12 growth fraction histologic prediction of recurrence $32 TLI vs Ki67 — comparison and prognostic recapitulation in nodal metastases $33 values 165-175 growth kinetics endocrine therapy Gompertzian vs. stochastic models — abstracts S67-S69 predictions for treatment 319-325 endothelial cells interactions with cell adhesion molecules in heat shock proteins breast cancer metastasis 239-260 constitutive overexpression of hsp27 in late epidermal growth factor (EGF) receptor passage breast cancer cells 177-186 targeted therapy with an EGF ligand fusion hsp27 and doxorubicin resistance 67-71 toxin 97-103 hsp70 in prognosis 67-71 erbB receptor family and ligands heat shock transcription factors and biological behavior S93 and loss of estrogen and heat regulation of erbB-2 oncogene hsp27 in late passage cells 177-186 overexpression during breast cancer evolution, HER-2/neu especially comedo DCIS 13-18 see erbB-2 estrogen receptor high-dose chemotherapy novel 80 kDa ER-related protein S94 with marrow support — abstracts S63-S66 point mutation and tamoxifen resistance $32 histologic grade variants in tamoxifen resistance 53-54 in Nottingham Prognostic Index applied to evolution of breast cancer Danish patients 281-290 clonal relationship of malignant and hyperplasia "premalignant" lesions 5-12 see premalignant breast disease Subject index, Vol. 32 339 imaging magnetic resonance imaging (MRI) (cont.) gadolinium-melanin polymer MRI contrast gadolinium-melanin polymer contrast agents agents targeted to breast cancer 119-135 targeted to breast cancer 119-135 immunocytochemistry male breast cancer multiple assays in fine needle aspirates 221-228 abstracts S90-S91 immunology mammography high CD46 and absent CD55 in malignant breast and screening — abstracts S84-S86 cells 213-219 cost-effectiveness targets S30 immunotherapy markers and immunology — abstracts S61-S62 abstracts S87-S89 anti-erbB-2 antibodies S30,S31 marrow support immunotoxins G-CSF S93 and ligand fusion toxins in targeted therapy 97- matrix metalloproteinases 103 in osteolytic bone metastasis 73-84 insulin-like growth factors (IGFs) MCF-7 cells and binding proteins, as targets for therapy 85- and targeted therapy with IGF binding proteins 95 85-95 binding proteins regulated by antiestrogens and constitutive overexpression of hsp27 in late progestins 153-164 passage cells 177-186 paracrine function of IGF-II S91 prostate specific antigen induction by steroids integrins (except estrogen) 291-300 involvement in metastasis — review 239-260 metastasis abstracts S83-S84 bone — cytokines, osteoclasts, and cell adhesion Ki67 growth fraction molecules 73-84 comparison with TLI in prognosis 165-175 involvement of cell adhesion molecules — in fine needle aspirates 221-228 review 239-260 kinetics of breast tumor growth ploidy and S-phase in primary tumors vs. their Gompertzian vs. stochastic models — nodal metastases 197-202 predictions for treatment 319-325 microdissection in analyzing clonal relationship of malignant and laminins "premalignant" lesions 5-12 involvement in metastasis — review 239-260 molecular biology in osteolytic bone metastasis 73-84 abstracts S75-S77 ligand fusion toxins monoclonal antibodies EGF/diphtheria toxin — preclinical and clinical 323/A3 in targeted MRI contrast agent 119-135 studies 97-103 83D4 against tumor-associated Tn-related liposomes epitope 139-152 in reducing toxicity of alkylphosphocholines mucins 269-279 compared with acidic tumor-associated Tn- loss of heterozygosity related antigen 139-152 in analyzing clonal relationship of malignant and "premalignant" lesions 5-12 in identifying tumor suppressor genes 19-38 neoadjuvant chemotherapy abstracts S62-S63 magnetic resonance imaging (MRI) neural networks detection and wire localization of an occult in integration of prognostic factor data 105- breast cancer 327-330 112,113-118 340 Subject index, Vol. 32 nm23 prognostic factors review of tumor suppressor genes in breast abstracts S46-S54 cancer 28-29 gene alterations S92 Nottingham Prognostic Index heat shock protein hsp70 67-71 applied to 9149 Danish patients 281-290 low urine and plasma androgens and poor survival 203-212 occult breast cancer methods for integration 105-112,113-118 detection and wire localization 327-330 Nottingham Prognostic Index applied to Danish oncogenes patients 281-290 and tumor suppressor genes — abstracts S74- p53 41-44 S75 platelet derived growth factor — an adverse bcl-2 regulation by estrogens S31 predictor 229-233 osteoclasts prostate specific antigen vs. ER, PgR, p53 301- role in osteolytic bone metastases 73-84 310 TLI vs Ki67 growth fractions 165-175 uPA, PAI-1, and cathepsin D S$29,S30 p53 proliferative rate in breast cancer prognosis and response to TLI vs Ki67 — comparison and prognostic therapy 39-47 values 165-175 overexpression during breast cancer evolution, prostate specific antigen (PSA) especially comedo DCIS 13-18 in 29% of breast tumor extracts 301-310 review of tumor suppressor genes in breast induction by steroids (except estrogen) in breast cancer 23-25 cancer cell lines 291-300 p53 protein proteases in fine needle aspirates 221-228 as prognostic factors — abstracts S51 paracrine interactions psychological and social aspects of breast cancer new human breast cancer line in nude mice — abstracts S44-S46 stromal dependence 187-196 patient management issues radiation therapy abstracts S71-S73 abstracts S42-S43 phosphocholines, alkyl without local boost, in conservative surgery with antitumor activity in ER-negative tumors 269- clear margins 261-267 279 recursive partitioning platelet derived growth factor (PDGF) in integration of prognostic factor data 105-112 an adverse prognostic factor 229-233 retinoblastoma (rb) gene ploidy review of tumor suppressor genes in breast in primary tumors vs. their nodal metastases cancer 20-23 197-202 retinoids polyamine biosynthesis inhibitors altered gene expression and inhibition of therapeutic effects S94 estrogen trans-activation S94 premalignant breast disease risk factors clonal relationship with later invasive lesion 5- abstracts S89-S90 12 immunohistochemical markers of progression S-phase stages 13-18 in primary tumors vs. their nodal metastases molecular genetics S29 197-202 progestins see also proliferative rate, thymidine labeling, regulation of IGF binding proteins 153-164 Ki67 Subject index, Vol.32 341 San Antonio Breast Cancer Symposium T47-D cells (cont.) 1994 abstracts S29-S94 prostate specific antigen induction by steroids 1994 program S3-S28 (except estrogen) 291-300 screening tamoxifen and mammography — abstracts S84-S86 effects and compliance monitored by flow signal transduction cytometry 57-65 interference by inhibiting AP-1 S91 mechanisms of resistance 49-55 special issues prevention trial — gynecologic assessment S29 San Antonio breast cancer SPORE 1-135 tamoxifen resistance SPOREs in breast cancer ER mutation; ER, PgR, pS2 expression changes San Antonio translational research 1-135 $32 statistical methods targeted therapy for integration of prognostic factor data 105- EGF/diphtheria toxin studies 97-103 112,113-118 IGF binding proteins 97-103 stress response thymidine labeling index (TLI) see heat shock proteins comparison with Ki67 growth fraction in stromal interactions prognosis 165-175 new human breast cancer line in nude mice — effect of primary chemotherapy, vs. tumor stromal dependence 187-196 response and relapse rate 311-318 surgery Tn antigen abstracts — S69-S71 related epitope associated with tumor cells 139- axillary dissection — abstracts $39-S41 152 breast conservation with clear margins — toremifene radiation therapy 261-267 resensitizing drug-resistant cells 57-65 breast conservation — abstracts $41-S42 translational research in breast cancer lumpectomy margin status and breast San Antonio SPORE overview 1-4 conservation S30 tumor biology abstracts S57-S60 tumor suppressor genes T47-D cells abstracts S74-S75 IGF binding proteins regulated by antiestrogens review of roles in breast cancer 19-38 and progestins 153-164 see also p53, retinoblastoma, etc.